Publications – Center for Communicable Disease Dynamics

Addendum: Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China.

Author(s): Wu JT, Leung K, Kishore N, Niehus R, De Salazar PM, Cowling BJ, Lipsitch M, Leung GMJournal: Nat MedPMID: 32661399 May 2020

On 17 April 2020, the Wuhan Municipal Health Commission revised the official COVID-19 death counts in Wuhan up by 1,290…

Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China.

Author(s): Wu JT, Leung K, Bushman M, Kishore N, Niehus R, De Salazar PM, Cowling BJ, Lipsitch M, Leung GMJournal: Nat MedPMID: 32284616 March 2020

As of 29 February 2020 there were 79,394 confirmed cases and 2,838 deaths from COVID-19 in mainland China. Of these,…

Distinguishing Causation From Correlation in the Use of Correlates of Protection to Evaluate and Develop Influenza Vaccines.

Author(s): Lim WW, Leung NHL, Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJJournal: Am J EpidemiolPMID: 31598648 March 2020

There is increasing attention to the need to identify new immune markers for the evaluation of existing and new influenza…

Burden of influenza-associated outpatient influenza-like illness consultations in China, 2006-2015: A population-based study.

Author(s): Feng L, Feng S, Chen T, Yang J, Lau YC, Peng Z, Li L, Wang X, Wong JYT, Qin Y, Bond HS, Zhang J, Fang VJ, Zheng J, Wu P, Jiang H, He Y, Cowling BJ, Yu H, Shu Y, Lau EHYJournal: Influenza Other Respir VirusesPMID: 31872547 December 2019

Human influenza virus infections cause a considerable burden of morbidity and mortality worldwide each year. Understanding regional influenza-associated outpatient burden…

Case-based surveillance of antimicrobial resistance with full susceptibility profiles.

Author(s): Ryu S, Cowling BJ, Wu P, Olesen S, Fraser C, Sun DS, Lipsitch M, Grad YHJournal: JAC Antimicrob ResistPMID: 32280945 December 2019

Surveillance of antimicrobial resistance (AMR) is essential for clinical decision-making and for public health authorities to monitor patterns in resistance…

The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology.

Author(s): Chua H, Feng S, Lewnard JA, Sullivan SG, Blyth CC, Lipsitch M, Cowling BJJournal: EpidemiologyPMID: 31609860 October 2019

The test-negative design is an increasingly popular approach for estimating vaccine effectiveness (VE) due to its efficiency. This review aims…

Effectiveness of influenza vaccination on influenza-associated hospitalisations over time among children in Hong Kong: a test-negative case-control study.

Author(s): Feng S, Chiu SS, Chan ELY, Kwan MYW, Wong JSC, Leung CW, Chung Lau Y, Sullivan SG, Malik Peiris JS, Cowling BJJournal: Lancet Respir MedPMID: 30442587 August 2019

The protection conferred by influenza vaccination is generally thought to last less than a year, necessitating annual revaccination. However, the…

Determinants of methicillin-resistant Staphylococcus aureus (MRSA) prevalence in the Asia-Pacific region: A systematic review and meta-analysis.

Author(s): Lim WW, Wu P, Bond HS, Wong JY, Ni K, Seto WH, Jit M, Cowling BJJournal: J Glob Antimicrob ResistPMID: 30145271 August 2019

Published literature on methicillin-resistant Staphylococcus aureus (MRSA) in the Asia-Pacific region was reviewed to document the prevalence of MRSA in…

Age-specific differences in the dynamics of protective immunity to influenza.

Author(s): Ranjeva S, Subramanian R, Fang VJ, Leung GM, Ip DKM, Perera RAPM, Peiris JSM, Cowling BJ, Cobey SJournal: Nat CommunPMID: 30971703 August 2019

Influenza A viruses evolve rapidly to escape host immunity, causing reinfection. The form and duration of protection after each influenza virus…

Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: A Systematic Review and Meta-analysis.

Author(s): Ng TWY, Cowling BJ, Gao HZ, Thompson MGJournal: J Infect DisPMID: 30551178 April 2019

A number of enhanced influenza vaccines have been developed for use in older adults, including high-dose, MF59-adjuvanted, and intradermal vaccines.